MedTrace Logo

Study to Evaluate the Safety and Efficacy of PIPE-307 in Subjects With Relapsing-Remitting Multiple Sclerosis

NCT06083753 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 182

Last updated 2025-10-23

No results posted yet for this study

Summary

This is a randomized, double-blind study of PIPE-307 or placebo in subjects with relapsing-remitting multiple sclerosis. Subjects will be randomized into 1 of 3 separate cohorts (1:1:1 randomization ratio, PIPE-307 Dose A:PIPE-307 Dose B: Placebo) for a total duration of approximately 30 weeks.

Conditions

  • Relapsing Remitting Multiple Sclerosis

Interventions

DRUG

PIPE-307 Dose A

Subjects will receive daily oral doses of PIPE-307

DRUG

PIPE-307 Dose B

Subjects will receive daily oral doses of PIPE-307

DRUG

Placebo

Subjects will receive daily oral matching dose of Placebo

Sponsors & Collaborators

  • Contineum Therapeutics

    lead INDUSTRY

Principal Investigators

  • Stephen Huhn, MD · Contineum Therapeutics

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-06
Primary Completion
2025-07-14
Completion
2025-08-04
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06083753 on ClinicalTrials.gov